Table 2.
Therapeutic interventions, outcomes, and cause of death of the patients
| rhTM group (n=11) | Non-rhTM group (n=11) | P-value | |
|---|---|---|---|
| BAL available, n (%) | 6 (54) | 2 (18) | 0.18* |
| Neutrophils in BAL (%) | 36.0±34.2 | 66.0±35.0 | 0.22# |
| Lymphocytes in BAL (%) | 13.5±15.7 | 7.0±5.4 | 0.66# |
| Corticosteroid pulse therapy, n (%) | 11 (100) | 10 (90) | 1.0* |
| Immunosuppressants other than corticosteroid, n (%) | 9 (81) | 7 (63) | 0.63* |
| Nasal high flow, n (%) | 1 (9) | 2 (18) | 1.0* |
| Mechanical ventilation, n (%) | 6 (54) | 5 (45) | 1.0* |
| NIPPV, n (%) | 6 (54) | 5 (45) | 1.0* |
| IMV, n (%) | 0 (0) | 0 (0) | 1.0* |
| Broad spectrum antibiotics therapy, n (%) | 11 (100) | 11 (100) | 1.0* |
| Death | |||
| 30 days death, n (%) | 2 (18) | 6 (54) | 0.18* |
| 90 days death, n (%) | 4 (36) | 10 (90) | 0.023* |
| Cause of death | |||
| Respiratory failure, n (%) | 3 (75) | 10 (100) | 0.28* |
| Drug-induced hepatic and renal failure, n (%) | 1 (25) | 0 (0) | 0.28* |
Notes: Data are expressed as mean ± standard deviation.
#
Mann–Whitney U-test and
*
Fisher’s exact test.
Abbreviations: rhTM, recombinant human thrombomoduline; BAL, bronchoalveolar lavage; NIPPV, noninvasive positive pressure ventilation; IMV, invasive mechanical ventilation.